OR WAIT null SECS
Be The Match BioTherapies and TrakCel have announced a collaboration to provide integrated solutions for companies developing cell and gene therapies.
Solutions provider, Be The Match BioTherapies, and software developer, TrakCel, have announced a collaboration to provide integrated solutions for companies developing cell and gene therapies in a June 18, 2019 press release.
The strategic partnership is aimed at combining services and technology platforms that will help improve operations of cell and gene therapy supply chain. The companies will identify the challenges facing developers of cell and gene therapies to be able to provide the optimal integrated solutions.
“Be The Match BioTherapies and TrakCel share the goal of ensuring that the next generation of cell and gene therapies can be developed efficiently and delivered to patients safely and reliably,” said Chris McClain, vice-president, sales and new business development, Be The Match BioTherapies, in the release. “This collaboration will allow us to develop the custom solutions best suited for each individual program and patient population.”
“Clinical and commercial advances in cell and gene therapies continue to progress dramatically. However, the resultant increases in complexity and stakeholders involved in the supply chain can leave it stretched and fragmented, potentially exposing patients to unnecessary risks,” added Ravi Nalliah, CEO, TrakCel. “As a result, TrakCel is continuing to sign partnerships with relevant industry providers to ensure the ever-growing supply chain can be effectively managed. This specific partnership with Be The Match BioTherapies will enable us to provide a more standardized and streamlined cell and gene therapy development process. That, in turn, will accelerate the delivery of vital new therapies to patients.”
Source: Be The Match BioTherapies